Form 4: Acadia Pharmaceuticals CEO Acquires Stock Options and Restricted Stock Units

CEO Catherine Owen Adams reports acquisition of stock options and restricted stock units in Acadia Pharmaceuticals.

Summary

• Catherine Owen Adams, CEO of Acadia Pharmaceuticals, filed a Form 4 indicating changes in beneficial ownership.
• On March 24, 2025, Adams acquired 319,976 stock options with an exercise price of $17.23.
• These options vest over time, with 25% vesting on March 24, 2026, and the remainder in 36 equal monthly installments.
• Adams also acquired 94,039 restricted stock units (RSUs) that vest in four equal annual installments beginning March 24, 2026.
• Following these transactions, Adams directly owns 319,976 stock options and 94,039 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options and RSUs could be interpreted as a positive sign of confidence, but it's a standard practice.

Positives

• The acquisition of stock options and RSUs by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the options and RSUs align the CEO's interests with the long-term success of the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention.
• The specific terms of these grants (e.g., vesting period, exercise price) are generally aligned with industry benchmarks for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of stock options and RSUs as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates

Keywords

Form 4, stock options, restricted stock units, Acadia Pharmaceuticals, CEO, Catherine Owen Adams, beneficial ownership, ACAD